Introduction
============

As one of the most common malignant tumors among women, breast cancer is the second and common cause of cancer-related death in women ([@B30]; [@B2]). Chemotherapy has become one of the most mature and common treatment option for breast cancer ([@B10]; [@B22]; [@B28]). Doxorubicin (DOX) is an anthracycline non-specific broad-spectrum anticancer drug that is widely used to treat breast cancer. Doxorubicin can exert its effects by elevating reactive oxygen species (ROS) thereby activating of caspase and ultimately leading to apoptosis ([@B23]; [@B4]). However, serious side effects, such as myelosuppression, cardiotoxicity, and drug resistance, are the major clinical chemotherapeutic drawbacks of DOX.

It has been proposed that combination therapeutics plays a synergistic effect and can enhance efficacy and reduce the toxicity of chemotherapy ([@B35]; [@B3]; [@B14]; [@B26]). [@B6] reported that the use of HO-3867, which is a synthetic curcumin analog, combined with DOX, in low doses to achieve enhanced cell death and reduced myocardial toxicity. And the increased generation of ROS, thereby resulting in oxidative damage to the cellular constituents, is widely exploited for therapeutic benefits on cancer ([@B20]; [@B25]; [@B39]). Fe, which plays a role in several types of cell death, has long been associated with toxicity because it induces hydroxyl radical (OH⋅), which is a ROS formed via Fenton reaction ([@B7]; [@B27]; [@B37]). Using ROS-producing agents could enhance the anticancer activity of DOX in cancer therapy through ROS-mediated apoptosis ([@B34]; [@B31]), autophagy ([@B11]), and ferroptosis ([@B38]). [@B9] identified the synergistic effect of DOX/ selenocystine sensitized to DOX by through ROS overproduction. [@B5] fabricated assembled metal-phenolic network Nps as a novel ROS promoted synergistic nanomedicine platform for cancer therapy. This observation inspires us to import an iron-supply system in combination with DOX to elicit a synergistic effect on the cancer therapy.

Recently, researchers attempted to build some drug carrier systems to load and transport DOX overcoming the low bioavailability, poor absorption, and high toxicity of DOX ([@B35]; [@B14]; [@B13]). Particularly, polydopamine (PDA), which is a natural-inspired polymer, is an appealing material as drug carrier due to its good biocompatibility ([@B18]; [@B13]; [@B24]). Considering its abundant aromatic rings, PDA NPs could be an efficient platform for loading DOX through π--π stacking and hydrogen-bonding interactiron. Meanwhile, the existence of phenolic hydroxyl groups on the surface makes it suitable for further modification with PEG, which could endow nanoparticles excellent physiological stability of NPs ([@B16]). More attractively, the phenolic surface have excellent chelating ability with metal ions such as Mn ([@B21]; [@B33]), Cu ([@B12]), and Fe ([@B15]).

Keep all the issues in mind, we hypothesized that the Fe-chelated PDA nanoparticles with DOX loading could act as an Fe-supply system used for Fe and DOX combined cancer theranostics, as shown in [Figure 1](#F1){ref-type="fig"}. The designed DOX\@Fe-PDA/folic acid (FA)-PEG could be provided with several advantages, as follows: ([@B30]) Combination therapy. The chemotherapy drug DOX undergoes redox cycles to generate and increase H~2~O~2~ in living cells. The released Fe from PDA further reacts with H~2~O~2~ to generate hydroxyl radical via Fenton reaction and induces cell death. In combination with Fe, DOX was prone to kill cancer cells efficiently ([@B2]). Biocompatibility and safety. PDA, which is a natural biopolymer, possesses biocompatibility. The coated PEG and chelated Fe of PDA Nps were metabolic. Meanwhile, the pH-triggered release performance of PDA in tumor microenvironment, avoids damage to surrounding tissues. The PEG-coating can help Nps to ameliorate long-term circulation ([@B10]). Tumor targeted. Considering folate receptor overexpression on the surface of breast cancer cells, the FA conjugated NPs may improve cell uptake via receptor mediated endocytosis. In summary, the DOX\@Fe-PDA/FA-PEG system could be used as potential combination chemotherapy nanodevice for breast cancer treatment.

![Schematic representation of DOX\@Fe-PDA/PEG-FA synthesis, targeted cell uptake and intracellular drug release and combination therapy.](fphar-10-00075-g001){#F1}

Materials and Methods {#s1}
=====================

NPs Synthesis
-------------

The synthesis of NPs was modified based on the previously introduced procedure ([@B15]). In brief, 4.08 mg FeCl~3~ and 15 mg dopamine plus 10 mL of water were mixed and stirred at room temperature for 1 h. Then 500 mg Tris was added, and the mixture was stirred at room temperature for 1.5 h. The mixture was centrifuged at 12000 rpm for 15 min to obtain Fe-PDA NPs. A total of 3.85 mL Fe-PDA NPs (5.2 mg/mL) were mixed with 20 mg FA-PEG-SH, 4.7 mg Tris, and 100 μL *tris*(2-carboxyethyl)phosphine (8 mg/mL). The mixture was vigorously stirred for 1 h at room temperature. Then, the FA-PEG modified NPs (Fe-PDA/PEG-FA) were purified via centrifugation and washed with deionized water.

Drug Loading
------------

A total of 2 mg adriamycin hydrochloride were added into 300 μL of dimethyl sulfoxide and 8.2 μL of triethylamine was added. The mixture was stirred in dark at room temperature for 12 h to desalinate hydrochloride. Then, the neutral DOX (2 mg) above-mentioned was added dropwise to 1 mL of Fe-PDA/FA-PEG NPs (10 mg/mL). Afterward, Tris (2.42 mg) was added and volume of 3 mL was obtained by adding distilled water. After vigorous stirring for 24 h in the dark, free DOX was removed via centrifugation at 12000 rpm for 10 min, then washed with phosphate buffer solution (PBS) and stored at 4°C in the dark. The DOX loading capacity of NPs was determined by UV-Vis spectrophotometer at the wavelength of 480 nm. The encapsulation efficiency (EE) of DOX was calculated by the following equation: EE = (initial amount of feeding drugs -- free drugs)/initial amount of feeding drugs.

NPs Characterization
--------------------

The size and Zeta potential of the prepared NPs were measured by dynamic light scattering-autosizer (DLS) on Zetasizer Nano ZS90 (Malvern Instruments, Malvern, United Kingdom). The liquid sample was sonicated before measurement. Three independent test results were recorded. The shape and surface morphology of the NPs were imaged by a transmission electron microscope (TEM, JEM-1230; JEOL, Tokyo, Japan). TEM, energy dispersive X-ray spectroscopy (EDS) and corresponding EDS-mapping were adopted for morphology and elemental distribution analyses on the JEM-1230 electron microscope operated at 200 kV. The chemical composition and structural changes of NPs were analyzed by Fourier transform infrared (FT-IR) spectroscopy (VERTEX 70; Bruker, Bremen, Germany). The IR spectra of the samples were obtained in the range of 4000 and 500 cm^-1^.

*In vitro* Drug Release Profiles
--------------------------------

The *in vitro* DOX release behavior of DOX\@Fe-PDA/FA-PEG was tested as reported previously ([@B16]). Briefly, DOX\@Fe-PDA/FA-PEG was dispersed in 2 mL PBS with the pH of either 7.2 or 5.5. The tube was shaken at 37°C with 100 rpm in dark. At appropriate time points, the full release buffer was collected via centrifugation at 12000 rpm for 10 min, and replaced with 2 mL of fresh PBS. The amount of released drug DOX was quantified by a UV spectrophotometer at the wavelength of 480 nm. The correlation between the accumulative DOX released from NPs and time was plotted.

Cell Culture
------------

The *in vitro* cell cytotoxicity cellular uptake and ROS measurement were assessed on human breast cancer cell line MCF-7, which was purchased from American Type Culture Collection. Cells were incubated at 37°C with modified Eagle's medium (MEM) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin in a 5% CO~2~ atmosphere.

Cellular Uptake Study
---------------------

A total of 2 × 10^5^ cells/well MCF-7 cells were seeded in 6-well plates for 24 h. Then, the samples (free DOX, DOX\@Fe-PDA/FA-PEG) were added to each well (equivalent DOX concentration of 10 μg/mL) and the cells were incubated at 37°C for an appropriate time at an additional of 24 h. Afterward, the cells were washed with PBS and stained by Hoechst 33342 (Sangon Biotech, Shanghai, China). Confocal laser scanning microscopy (CLSM) imaging was performed on LSM 410 fluorescence microscope (Zeiss, Jena, Germany). The fluorescence signal of DOX was excited at 488 nm and measured at 610 nm. The fluorescence signal stained by Hoechst 33342 was excited at 405 nm and detected at 490 nm.

*In vitro* Cytotoxicity by Using MTT Assay
------------------------------------------

MCF-7 cells were seeded in 96-well plates at a density of 5000 cells per well and incubated in 100 mL of medium for 24 h to allow attachment. Then, the cells were incubated with free DOX and DOX\@Fe-PDA/FA-PEG (DOX concentration of 0.1093, 0.2187, 04375, 0.875, 1.75, and 3.5 μg/mL) for 24 and 48 h, respectively. A total of 20 μL MTT solution (5 mg/mL) were added to each well and incubated for 4 h. The crystals were dissolved by adding DMSO. The optical density value of each well was measured at 490 nm by an iMark plate reader (Bio-Rad, Berkeley, CA, United States). All data were obtained in quadruplicate.

Intracellular ROS Content Measurement
-------------------------------------

MCF-7 cells were seeded on 6-well plates at a density of 2 × 10^5^ cells per well. Then the cells were incubated with free DOX and DOX\@Fe-PDA/FA-PEG (equivalent DOX concentration of 10 μg/mL) for 8 h at 37°C. Afterward, diluted 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Solarbio, Beijing, China), which is a cell-permeable fluorescent probe, were added. Then, the cells were placed in a 6-well plate at 37°C and incubated for another 30 min. The cells were washed for three times with serum-free medium to remove DCFH-DA completely and finally observed using fluorescence microscope.

Data Analysis Methodology
-------------------------

All experiments were performed at least three times unless otherwise stated. All experimental data were expressed as mean ± SD and both were treated with SPSS 18.0 (SPSS, Chicago, IL, United States).

Results and Discussion
======================

DOX@ Fe-PDA/FA-PEG Synthesis and Characterization
-------------------------------------------------

The design and synthetic strategy of DOX\@Fe-PDA/FA-PEG is shown in [Figure 1](#F1){ref-type="fig"}. First, the Fe-PDA was synthesized using an oxidative self-polymerization method according to previously literature ([@B15]). In addition, folic acid conjugated PEG was introduced to modify the PDA in enhancing the targeting effect and improving the stability of the NPs. Finally, DOX was loaded via diffusion in an aqueous media. The mean hydrodynamic sizes of DOX\@PDA/FA-PEG, DOX\@Fe-PDA/FA-PEG and the unloaded Fe-PDA/FA-PEG were 239.5 ± 28.82, 267.7 ± 34.16, and 283.22 ± 21.6 nm, respectively, with a narrow size distribution as demonstrated in [Figure 2A](#F2){ref-type="fig"}. This particle size is theoretically suitable for cellular uptake and tumor cell permeation duo to EPR effect ([@B19]). Zeta potential plays a key role in the stability and penetration through cell membranes for Nps ([@B1]). Considering the presence of the carboxyl group of FA, the zeta potentials of all NPs are negative ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}), thereby indicating that these Nps were stable *in vivo* by electrostatic repulsion, which is the basis of drug delivery ([@B32]). The zeta potential of Fe-PDA/FA-PEG (-30 mV) is slightly lower than that of Fe-PDA/FA-PEG loaded with DOX (-27.2 mV) ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}), thereby suggesting that the positively charged amino groups on DOX partially neutralized the negative charge.

![The characterization of different nanoparticl nanoparticles. **(A)** Size distributions of Fe-PDA/FA-PEG, DOX\@Fe-PDA/FA-PEG, DOX\@PDA/FA-PEG. **(B)** TEM image of PDA/FA-PEG, DOX\@Fe-PDA/FA-PEG, DOX\@PDA/FA-PEG. Scale bar: 100 nm.](fphar-10-00075-g002){#F2}

The morphologies of Fe-PDA/FA-PEG (wihout DOX loaded), DOX\@PDA/FA-PEG (without Fe chelated), DOX\@Fe-PDA/FA-PEG were observed by TEM. The results revealed that the DOX-loaded PDA/FA-PEG exhibited a spherical and uniform morphology ([Figure 2B](#F2){ref-type="fig"}). The particle size observed by TEM was substantially the same as the particle size measured by DLS. Scanning electron microscopy used to perform accurate elemental analysis of Nps. Using dark field image (DFI) characterization, electron energy loss spectroscopy (EELS), energy dispersive spectroscopy (EDS), and corresponding element mapping (EDS mapping) ([Figure 3](#F3){ref-type="fig"}) clearly show the morphological structure of the nanoparticles and distribution of four elements (C, N, O, Fe). The results showed that the coexistence of C, N, O, and Fe signals coexisted in the EDS spectra of Fe-PDA and Fe-PDA/FA-PEG. The uniform distribution of C, N, O, and Fe was confirmed by EDS element mapping. This result indicated the success and dispersion loads of Fe, PDA, and PEG in the DOX-loaded Fe-PDA/FA-PEG and unloaded Fe-PDA/FA-PEG. However, in the EDS element mapping of PDA, only C, N, and O signals coexisted and were distributed, thereby indicating the success and dispersion load of PDA and PEG in the DOX-loaded PDA/FA-PEG. Further, the FR-IR was performed to evaluat the surface characterization. As shown in [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}, the, the characteristic peaks of N-H bending vibration appearing at 1512, 1589, and 3250 cm^-1^. The peaks at 1493 and 1445 cm^-1^ can be ascribed to the existence of FA. Compared with PDA, the peaks of PEG at 1128 cm^-1^ (C-O-C stretching) were observed.

![Dark-field image, and corresponding area-elemental mappings of PDA/FA-PEG, DOX\@Fe-PDA/FA-PEG, DOX\@PDA/FA-PEG. Scale bar: 50 nm.](fphar-10-00075-g003){#F3}

*In vitro* pH-Stimuli Release Study
-----------------------------------

At a drug to Fe-PDA/FA-PEG feeding ratio of 1:5 in weight, the encapsulation efficiency of DOX in the Fe-PDA/FA-PEG was 76.6 ± 5.2% determined by UV-Vis absorption spectrophotometer. As PDA NPs exist abundant aromatic rings and phenolic hydroxyl groups, the DOX was loaded through π--π stacking and hydrogen-bonding interaction. Subsequently, the pH dependent release capability of DOX\@Fe-PDA/FA-PEG was investigated at 37°C under the pH levels of 7.2 and 5.5. The accumulative drug release kinetics curves are shown in [Figure 4](#F4){ref-type="fig"}. The drug release of both the DOX-loaded Fe-PDA/FA-PEG was significantly pH-dependent. As shown in [Figure 4](#F4){ref-type="fig"}, the release of the drug was as low as 25.5% at the of pH 7.2 within 36 h, and even 30.1% within 48 h. However, under acidic conditions, the release amount reached 34.6% within 8 h at the pH of 5.5, and the release rate at 48 h was 47.2%. This indicated that the drug-loaded Nps can cause the drug release under acidic condition, mainly due to the extremely high pH responsiveness of the PDA-modified NPs. This phenomenon allowed the rapid drug release at low pH. Considering the acidic microenvironment of the tumor and intracellular acidic endosomes and lysosomes, drugs are released only after being phagocytized by lysosomes in tumor cells, thereby effectively reducing drug waste and enhancing the antitumor effects by rapidly increasing the lysosome concentration ([@B8]).

![*In vitro* drug release profile of DOX\@Fe-PDA/FA-PEG in media with different pH value (pH 7.2 and 5.5).](fphar-10-00075-g004){#F4}

Cellular Uptake
---------------

To study the cellular uptake and the intracellular distribution, we investigated the intracellular delivery of free DOX by using a confocal microscopy. [Figure 5A](#F5){ref-type="fig"} shows the fluorescence of DOX distrubuted in the cytoplasm and cell nuclei after incubation with free DOX for 1 h. However the red flourescence with NPS observed in nucleus was not obvious. Based on the different intracellular fates of DOX, it was indicated that the NPs were internalized into cell mainly via endocytic pathway. And then we continued to incubate for another 9 h and observed under a fluorescence microscope as shown in [Figure 5B](#F5){ref-type="fig"}. Apparently, the uptake intensities of DOX-loaded NPs was higher than that of free DOX, and it was contributed by the targeting effect of folate receptor. Moreover, the cell uptake intensities of DOX-loaded NPs were positive correlation with incubation time. While the fluorescence intensity of free DOX in the cells is weaker than that of the doxorubicin-loaded NPs, indicating that the intracellular free DOX decays with time. According to the *in vitro* drug release profiles, this phenomenon proves that the DOX-loaded Nps have a sustained release effect, which may help to enhance the cytotoxicity of DOX.

![Confocal laser scanning microscopy (CLSM) images of MCF-7 cells after incubation with free DOX, DOX-@ Fe-PDA/FA-PEG for 1 h **(A)**, and 9 h **(B)**. The cells were stained by Hoechst (blue) and drug DOX was red.](fphar-10-00075-g005){#F5}

Cytotoxicity of DOX-Loaded NPs
------------------------------

To assess the cytotoxicity of DOX\@Fe-PDA/FA-PEG, we performed the MTT assays. In order to confirm the high biocompatibility and safety of the NPs, we incubated the Fe-PDA/FA-PEG NPs with MCF-7 cells. As shown in [Figure 6A](#F6){ref-type="fig"}, the Fe-PDA/FA-PEG NPs without drug-loading exhibited a negligible cytotoxicity the concentration ranging from 0 to 250 μg/mL for 48 h. This result suggested that the prepared material possessed high biocompatibility and low cell cytotoxicity. Then, we compared the results of cytotoxicity of free DOX and DOX-loaded Nps at 24 and 48 h. [Figure 6B,C](#F6){ref-type="fig"} shows the cytotoxicity of DOX on MCF-7 was time and dose-dependent. As the DOX concentration and incubation time prolonged, the greater the toxicity of the drug to MCF-7 cell. Apparently, the cytotoxicity of DOX-loaded Fe-PDA/FA-PEG NPs was greater than that free DOX, thereby demonstrating that Fe enhanced the killing effect of DOX on the MCF-7 cells. And it was found that the 48 h of incubation exhibited a considerable killing effect on MCF-7 cells than 24 h. This result further confirmed the sustained release of NPs.

![Relative viabilities of MCF-7 cells after incubated with PDA/FA-PEG for 48 h **(A)** and free DOX and DOX\@Fe-PDA/FA-PEG at different concentrations 24 h **(B)** and 48 h **(C)**.](fphar-10-00075-g006){#F6}

ROS Detection
-------------

Reactive oxygen species -induced cell death has been a widely uesed strategy for tumor therapy ([@B20]; [@B7]; [@B25]; [@B39]). As we know, DOX could activate nicotinamide adenine dinucleotide phosphate oxidases, and further produce ROS, which contribute to anticancer drug-induced toxicity ([@B4]; [@B26]). Recently, synergistic approaches by using ROS-producing agents with DOX have attracted considerable attention ([@B34]). Intriguingly, the presence of Fe (II and III) contributes to the enhanced chemotherapy efficacy by converting the accumulated H~2~O~2~ to the hydroxyl radical via Fenton reactions ([@B7]). To explore the underlying mechanism of enhanced antiproliferating effects of DOX\@Fe-PDA/FA-PEG further, we quantified the intracellular ROS by using 2′-7′-dichlorofuorescin diacetate. Compared with the control group, green fluorescence was observed after incubation with DOX and DOX\@Fe-PDA/FA-PEG ([Figure 7](#F7){ref-type="fig"}). In addition, cells treated with DOX-loaded Fe-PDA/FA-PEG had the highest fluorescence intensity, thereby indicating the highest ROS production. The results showed that the cells treated with DOX loaded Fe-PDA/FA-PEG can synergistically produce ROS to kill tumor cells. DOX used to undergo redox cycles to generate high H~2~O~2~ levels inside the cancer cells. After endocytosis by tumor cells, the DOX\@Fe-PDA/FA-PEG was decomposed by the acidic microenvironment. The elevated H~2~O~2~ of DOX can be further catalyzed by Fe ions via Fenton reaction to generate abundant highly toxic resulting in enhancing anticancer effects of DOX through oxidative damage to DNA, protein, and lipid ([@B20]; [@B25]; [@B39]). Previous investigations have developed iron-based nanomaterials, including iron nanometallic glasses and iron oxide, have been employed to upregulation of ROS by using the situ Fenton reaction ([@B36]; [@B17]; [@B29]). However, current iron-based nanomaterials is far from satisfactory. Some of the nanomaterials such as Fe^0^ nanoparticles ([@B36]) and iron oxide nanoplatform ([@B17]), are difficult to fabricate and the synthetic conditions generally are harsh and complicated. In this work, we synthesized the iron-chelated PDA NPs via a one-pot reaction and the FA-PEG as the surface ligand for tumor homing with a low cost and biocompable biocompatibility. And the pH-stimuli release profiles included being highly selective and logical, and amenable to activation by endogenous stimuli. This strategy present an approach for synergistic combination of ROS and chemotherapy to enhance the anticancer efficacy.

![The intracellular ROS stained with DCFH-DA in MCF-7 cells after incubation with free DOX, DOX\@Fe-PDA/FA-PEG, DOX\@PDA/FA-PEG for 8 h were measured by fluorescence microscopic.](fphar-10-00075-g007){#F7}

Conclusion
==========

In this study, we successfully fabricated a novel nanocarrier on the basis of Fe-chelated PDA nanoparticles used for Fe and DOX combined cancer theranostics through ROS over-generation. The obtained DOX\@Fe-PDA/FA-PEG Nps had a hydrodynamic size of about 250 nm, and the structure was characterized by DLS, TEM, EDS, and FT-IR. The *in vitro* drug release profile triggered by low intracellular pH indicated that the system demonstrated controlled therapeutic activity. Further, *in vitro* cell uptake studies indicate that DOX-loaded Fe-PDA /FA-PEG can be internalized by MCF-7 cells and exhibited high targeting efficiency due to specific recognition. The *in vitro* experiments demonstrated that DOX\@Fe-PDA/FA-PEG trigged the intracellular ROS overproduction, thereby enhancing the therapeutic effect on breast cancer. Taken together, this study provides a strategy to harness Fe-PAD nanocarrier for Fe and DOX combined cancer theranostics.
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